AVANOS MEDICAL (AVNS) Stock Price, News & Analysis

Company Overview

Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Key Stats

• Today's Range: $11.73 to $11.97
• 50-Day Range: $9.98 to $12.50
• 52-Week Range: $9.30 to $25.36
• Volume: 647,282 shs
• Average Volume: 821,409 shs
• Market Capitalization: $553.74 million
• P/E Ratio: 9.73
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

AVANOS MEDICAL Stock Analysis - MarketRank™

AVANOS MEDICAL scored higher than 82% of companies evaluated by MarketBeat, and ranked 320th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for AVANOS MEDICAL.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 31.06%

Earnings Growth

Earnings for AVANOS MEDICAL are expected to grow by 31.06% in the coming year, from $1.32 to $1.73 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AVANOS MEDICAL is 9.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 83.56.

Price to Earnings Ratio vs. Sector

The P/E ratio of AVANOS MEDICAL is 9.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 42.82.

Price to Book Value per Share Ratio

AVANOS MEDICAL has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.23% of the float of AVANOS MEDICAL has been sold short.

Short Interest Ratio / Days to Cover

AVANOS MEDICAL has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AVANOS MEDICAL has recently increased by 25.83%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AVANOS MEDICAL does not currently pay a dividend.

Dividend Growth

AVANOS MEDICAL does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.23% of the float of AVANOS MEDICAL has been sold short.

Short Interest Ratio / Days to Cover

AVANOS MEDICAL has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AVANOS MEDICAL has recently increased by 25.83%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.77

News Sentiment

AVANOS MEDICAL has a news sentiment score of 1.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for AVANOS MEDICAL this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for AVNS on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, AVANOS MEDICAL insiders have bought more of their company's stock than they have sold. Specifically, they have bought $659,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.64% of the stock of AVANOS MEDICAL is held by insiders.

Percentage Held by Institutions

95.17% of the stock of AVANOS MEDICAL is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AVNS Stock Analysis - Frequently Asked Questions

How have AVNS shares performed this year?

AVANOS MEDICAL's stock was trading at $15.92 at the beginning of the year. Since then, AVNS shares have decreased by 25.0% and is now trading at $11.9340.

How were AVANOS MEDICAL's earnings last quarter?

AVANOS MEDICAL, INC. (NYSE:AVNS) announced its earnings results on Tuesday, August, 5th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by $0.01. The firm earned $175 million during the quarter, compared to analyst estimates of $165.50 million. AVANOS MEDICAL had a positive trailing twelve-month return on equity of 6.16% and a negative net margin of 66.89%.
Read the conference call transcript.

Who are AVANOS MEDICAL's major shareholders?

AVANOS MEDICAL's top institutional investors include Armistice Capital LLC (4.39%), Brown Advisory Inc. (3.90%), Paradice Investment Management LLC (2.71%) and Geode Capital Management LLC (2.31%). Insiders that own company stock include Michael Greiner, Gary Blackford, Kerr Holbrook and Julie Ann Shimer.
View institutional ownership trends.

How do I buy shares of AVANOS MEDICAL?

Shares of AVNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AVANOS MEDICAL own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AVANOS MEDICAL investors own include JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Home Depot (HD), Netflix (NFLX) and Tesla (TSLA).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 8/29/2025
• Next Earnings (Estimated): 10/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:AVNS
• CIK: 1606498
• Web: avanos.com
• Phone: (844) 428-2667
• Fax: N/A
• Employees: 2,227
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($10.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 8.96
• P/E Growth: N/A
• Net Income: -$392.10 million
• Net Margins: -66.89%
• Pretax Margin: -68.91%
• Return on Equity: 6.16%
• Return on Assets: 4.57%

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 2.64
• Quick Ratio: 1.58

Sales & Book Value

• Annual Sales: $687.80 million
• Price / Sales: 0.80
• Cash Flow: $11.83 per share
• Price / Cash Flow: 1.00
• Book Value: $16.73 per share
• Price / Book: 0.71

Miscellaneous

• Outstanding Shares: 46,400,000
• Free Float: 45,177,000
• Market Cap: $548.91 million
• Optionable: Optionable
• Beta: 1.12